Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium I

2772 - VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Date

28 Sep 2019

Session

Presidential Symposium I

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Ovarian Cancer

Presenters

Robert Coleman

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

R.L. Coleman1, G.F. Fleming2, M.F. Brady3, E. Swisher4, K.D. Steffensen5, M. Friedlander6, A. Okamoto7, K. Moore8, N. Ben-Baruch9, T.L. Werner10, A. Oaknin11, J. Nam12, C.A. Leath III13, S. Nicum14, D. Cella15, D.M. Sullivan16, P.J. Ansell16, M. Dinh16, C. Aghajanian17, M.A. Bookman18

Author affiliations

  • 1 Gynecologic Oncology And Reproductive Medicine, The M. D. Anderson Cancer Center, 77030-3721 - Houston/US
  • 2 Department Of Medicine, The University of Chicago Medicine, Chicago/US
  • 3 Nrg Oncology Statistical And Data Center, Roswell Park Cancer Institute, Buffalo/US
  • 4 Department Of Obstetrics And Gynecology, University of Washington/Seattle Cancer Care Alliance, Seattle/US
  • 5 Department Of Oncology, Vejle Hospital, Vejle, Denmark, and University of Southern Denmark, Odense/DK
  • 6 Medical Oncology, Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney/AU
  • 7 Obstetrics And Gynecology, The Jikei University School of Medicine, Tokyo/JP
  • 8 Stephenson Cancer Center, University of Oklahoma Health Sciences Center, - - Oklahoma City/US
  • 9 Oncology, Kaplan Medical Center, Rehovot/IL
  • 10 Huntsman Cancer Institute, University of Utah, Salt Lake City/US
  • 11 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 12 Obstetrics/gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul/KR
  • 13 Division Of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham/US
  • 14 Department Of Oncology, Oxford University Hospitals, Oxford/GB
  • 15 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago/US
  • 16 Oncology, AbbVie Inc., North Chicago/US
  • 17 Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 18 Gynecologic Oncology, Kaiser Permanente Northern California, San Francisco/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2772

Background

This phase III randomized placebo (PL) controlled multinational trial evaluated whether progression-free survival (PFS) is increased when V is added to front-line carboplatin and paclitaxel (CP) and continued as maintenance in newly diagnosed HGSC pts considering BRCA mutations (m), homologous recombination deficiency (HRD), and neoadjuvant chemotherapy (NACT) utilization.

Methods

Previously untreated Stage III-IV HGSC pts were to receive 6 cycles (21-d interval) of CP using 3-wkly or wkly paclitaxel, following primary cytoreduction or NACT with interval cytoreduction. V or PL was administered during CP (150 mg BID PO) and as maintenance (400 mg BID for 30 cycles). Randomization was 1:1:1, stratified by Stage III vs IV, residual disease and regimen, region, and gBRCA status: Arm 1: CP + PL then PL maintenance Arm 2: CP + V then PL maintenance Arm 3: CP + V then V maintenance Primary endpoints were PFS (Kaplan-Meier) in Arm 3 vs 1 using hierarchical testing in BRCAm, HRD (incl. BRCAm), and whole populations by log-rank tests. Secondary endpoints were PFS (Arm 2 vs 1), overall survival, and disease related symptom scores. Germline and tissue BRCAm and HRD were determined by central testing.

Results

1140 pts were enrolled with 26% in BRCAm and 55% in HRD populations. Efficacy results summarized in Table. Relative CP dose intensities were similar between arms. Grade 3-4 adverse events (AE; Arm 3 vs 1) were similar during CP with the exception of thrombocytopenia (27% vs 8%); during maintenance, any grade 3-4 AE was higher for V treatment (45% vs 32%) but serious AEs were similar (17% vs 19%).Table:

LBA3

Population
BRCAmHRDWhole
Arm 3 n = 108Arm 1 n = 92Arm 3 n = 214Arm 1 n = 207Arm 3 n = 382Arm 1 n = 375
Median PFS (months)34.722.031.920.523.517.3
PFS HR (95% CI) P value0.44 [0.28, 0.68] < 0.0010.57 [0.43, 0.76] < 0.0010.68 [0.56, 0.83] < 0.001

BRCAm, BRCA mutated; HRD, homologous recombination deficient; HR, hazard ratio; P value by stratified log-rank test; PFS, progression-free survival.

Conclusions

V added to front-line CP and continued as monotherapy maintenance significantly extended PFS in all women with newly diagnosed HGSC without selection according to BRCAm or HRD status, or response to CP. Observed toxicities were consistent with known V safety profile.

Clinical trial identification

NCT02470585.

Editorial acknowledgement

Medical writing support was provided by Ana Mrejeru, Ph.D., of AbbVie.

Legal entity responsible for the study

AbbVie.

Funding

AbbVie.

Disclosure

R.L. Coleman: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Clovis Oncology; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (self): Esperance; Advisory / Consultancy: NCCN; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca/MedImmune; Advisory / Consultancy: Genmab; Advisory / Consultancy: GamaMabs Pharma; Advisory / Consultancy: Tesaro; Advisory / Consultancy, Research grant / Funding (self): OncoMed; Advisory / Consultancy: Sotio; Advisory / Consultancy: Oncolytics; Advisory / Consultancy: AbbVie/Stemcentrx; Research grant / Funding (self), Travel / Accommodation / Expenses: Merck; Research grant / Funding (self), Travel / Accommodation / Expenses: Array Biopharma; Travel / Accommodation / Expenses: Research to Practice; Travel / Accommodation / Expenses: GOG; Travel / Accommodation / Expenses: Sotio; Travel / Accommodation / Expenses: Vaniam Group; Research grant / Funding (self): Johnson & Johnson; Research grant / Funding (self): Abbott/AbbVie. G.F. Fleming: Research grant / Funding (self): Corcept Therapeutics; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Genentech; Research grant / Funding (self): Tesaro; Research grant / Funding (self): Syndax; Research grant / Funding (self): Forty Seven; Research grant / Funding (self): Iovance; Research grant / Funding (self): Syros; Research grant / Funding (self): Astex; Research grant / Funding (self): Merck. K.D. Steffensen: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AbbVie. M. Friedlander: Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Takeda; Research grant / Funding (self): BeiGene. A. Okamoto: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Chugai; Honoraria (self): MSD; Research grant / Funding (self): Kaken; Research grant / Funding (self): Mochida; Research grant / Funding (self): Kissei; Research grant / Funding (self): Pfizer. K. Moore: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution): Advaxis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Non-remunerated activity/ies: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: VBL Therapeutics; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Aravive; Advisory / Consultancy: Samumed; Advisory / Consultancy: OncoMed; Advisory / Consultancy: Pfizer/EMD Serono ; Advisory / Consultancy: Eisai; Research grant / Funding (institution): PTC Therapeutics; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Lilly Foundation; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Verastern; Research grant / Funding (institution): Agenus; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Forty Seven; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Novogen. N. Ben-Baruch: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Eli Lilly; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Research grant / Funding (self): AbbVie. T.L. Werner: Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Roche/Genentech; Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): AstraZeneca. A. Oaknin: Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Pharmamar; Advisory / Consultancy, Travel / Accommodation / Expenses: Clovis Oncology; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Immunogen ; Advisory / Consultancy: Genmab. J. Nam: Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Zeria Pharmaceutical Co.. C.A. Leath III: Honoraria (self), Research grant / Funding (institution): Mateon Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Celsion; Advisory / Consultancy: Unleash Immuno Oncolytics; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Plexxikon; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Syros; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Eisai. S. Nicum: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro. D. Cella: Advisory / Consultancy: AbbVie; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: PledPharma; Advisory / Consultancy: Puma Biotechnology; Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Shareholder / Stockholder / Stock options: FACIT.org; Research grant / Funding (institution): Genentech. D.M. Sullivan: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. P.J. Ansell: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. M. Dinh: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. C. Aghajanian: Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Mateon Therapeutics; Advisory / Consultancy: Immunogen; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Cerulean Pharma; Advisory / Consultancy: Eisai/Merck. M.A. Bookman: Non-remunerated activity/ies, Member, international protocol steering committee (AbbVie GOG3005): AbbVie; Non-remunerated activity/ies, protocol steering committee: Genentech-Roche; Non-remunerated activity/ies, protocol steering committee: ARAVIVE; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Merck; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.